Skip links

News

PharmaCielo Announces TSX Venture Exchange Approval of Warrant Extension

November 22, 2022 TORONTO, Canada and RIONEGRO, Colombia (November 22, 2022) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced

PharmaCielo Announces Q3 2022 Financial Results

October 31, 2022 In the first nine months of 2022, PharmaCielo has made shipments to 23 customers in nine countries, with continued growth expected for 2023. The Company has more than doubled Revenue to $3.8 million in the first nine months of 2022, compared to

PharmaCielo Announces Shipment of Dried Cannabis Flower to the Czech Republic, Representing the Company’s First Shipment of Medicinal Grade Dried Cannabis Flower into the EU

September 15, 2022 Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic, focused on medicinal grade cannabinoids. TORONTO, Canada and RIONEGRO, Colombia Colombia (September 15, 2022) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO,OTCQX: PCLOF), the Canadian parent
Mexico Flag

PharmaCielo Announces First Shipment to Mexican Joint Venture Partner

August 4, 2022 The Company has made a pre-commercial shipment of CBD isolate to its Mexican joint venture, to support product development by a Mexican phytotherapeutic company. TORONTO, Canada and RIONEGRO, Colombia (August 4, 2022) – PharmaCielo Ltd. (“PharmaCielo” orthe “Company”) (TSXV: PCLO, OTCQX: PCLOF),